CNBX Pharmaceuticals Inc.

AI-generated fair value estimate for this company.

Method: Liquidation/net-tangible-asset approach: company has $0 revenue, recent SEC filings describing 'cash strain, debt forbearance and major dilution,' and roughly 1.6 billion shares outstanding against a market cap of only about $160K; value assumes near-total impairment of net assets after liabilities, leaving only a nominal residual option value on its cannabis-related diagnostic/pipeline IP.

Reasoning: CNBX is a severely cash-strained, pre-revenue micro-cap biotech with no near-term financing visibility, so a standard DCF has no grounded inputs; a liquidation-style approach recognizing that equity holders are last in line behind creditors and that continued heavy dilution erodes per-share value is the most defensible method, even though it produces a value near zero.